Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

CYP2C9 and VKORC1 genotyping for the quality of long-standing warfarin treatment in Russian patients

Abstract

A total of 263 warfarin naive patients with indications to long-term anticoagulation were included in prospective multicenter study and randomized into Pharmacogenetics and Standard dosing groups. The loading warfarin dose in Pharmacogenetics group was calculated by Gage algorithm and corrected starting on day 5 of treatment according to INR. In Standard dosing group warfarin initial dose was 5 mg and starting on day 3 of treatment it was titrated according to INR. Pharmacogenetics dosing in comparison with prescription of starting dose of 5 mg decreased major bleedings (0 vs. 6, p = 0.031), time to target INR (11 [9–14] vs. 17 [15–24] days, p = 0.046), and frequency of INR fluctuations ≥4.0 (11% vs. 30.9%, p = 0.002). The advantages of the pharmacogenetics dosing were mainly achieved due to the patients with increased warfarin sensitivity.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schuünemann HJ, American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel Executive summary: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;2 Suppl:7S–47S.

    Article  Google Scholar 

  2. Holbrook AM, Pereira JA, Labiris R, McDonald H, Douketis JD, Crowther M, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med. 2005;165:1095–106.

    Article  CAS  Google Scholar 

  3. Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet. 1999;353:717–9.

    Article  CAS  Google Scholar 

  4. D’Andrea G, D’Ambrosio RL, Di Perna P, Chetta M, Santacroce R, Brancaccio V, et al. A polymorphism in the VKORC1 gene is associated with an inter-individual variability in the dose-anticoagulant effect of warfarin. Blood. 2005;105:645–9.

    Article  Google Scholar 

  5. Wadelius M, Chen LY, Eriksson N, Bumpstead S, Ghori J, Wadelius C, et al. Association of warfarin dose with genes involved in its action and metabolism. Hum Genet. 2007;121:23–34.

    Article  CAS  Google Scholar 

  6. Caldwell MD, Awad T, Johnson JA, Gage BF, Falkowski M, Gardina P, et al. CYP4F2 genetic variant alters required warfarin dose. Blood. 2008;111:4106–12.

    Article  CAS  Google Scholar 

  7. Rieder MJ, Reiner AP, Rettie AE. Gamma-glutamyl carboxylase (GGCX) tagSNPs have limited utility for predicting warfarin maintenance dose. J Thromb Haemost. 2007;5:2227–34.

    Article  CAS  Google Scholar 

  8. Eriksson N, Wallentin L, Berglund L, Axelsson T, Connolly S, Eikelboom J, et al. Genetic determinants of warfarin maintenance dose and time in therapeutic treatment range: a RE-LY genomics substudy. Pharmacogenomics. 2016;17:1425–39. https://doi.org/10.2217/pgs-2016-0061.

    Article  CAS  PubMed  Google Scholar 

  9. Johnson JA, Caudle KE, Gong L, Whirl-Carrillo M, Stein CM, Scott SA, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for pharmacogenetics-guided warfarin dosing: 2017 update. Clin Pharm Ther. 2017;102:397–404.

    Article  CAS  Google Scholar 

  10. Gage BF, Eby C, Johnson JA, Deych E, Rieder MJ, Ridker PM, et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharm Ther. 2008;84:326–31. https://doi.org/10.1038/clpt.2008.10.

    Article  CAS  Google Scholar 

  11. Li X, Li D, Wu J, Liu Z, Zhou H, Yin J. Precision dosing of warfarin: open questions and strategies. Pharmacogenomics J. 2019;19:219–29. https://doi.org/10.1038/s41397-019-0083-3.

    Article  CAS  PubMed  Google Scholar 

  12. Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, D’Angelo A, et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet. 1996;348:423–8.

    Article  CAS  Google Scholar 

  13. Mega JL, Walker JR, Ruff CT, Vandell AG, Nordio F, Deenadayalu N, et al. Genetics and the clinical response to warfarin and edoxaban: findings from the randomized, double-blind ENGAGE AF-TIMI 48 trial. Lancet. 2015;385:2280–7.

    Article  CAS  Google Scholar 

  14. Gage BF, Bass AR, Lin H, Woller SC, Stevens SM, Al-Hammadi N, et al. Effect of genotype-guided warfarin dosing on clinical events and anticoagulation control among patients undergoing hip or knee arthroplasty: the GIFT randomized clinical trial. JAMA. 2017;318:1115–24.

    Article  CAS  Google Scholar 

  15. Hao Y, Yang J, Zheng X, Hu Y, Yan X, Zhang L. Chinese patients with heart valve replacement do not benefit from warfarin pharmacogenetic testing on anticoagulation outcomes. Ther Drug Monit. 2019;41:748–54. https://doi.org/10.1097/ftd.0000000000000664.

    Article  CAS  PubMed  Google Scholar 

  16. Hillman MA, Wilke RA, Yale SH, Vidaillet HJ, Caldwell MD, Glurich I, et al. A prospective, randomized pilot trial of model‐based warfarin dose initiation using CYP2C9 genotype and clinical data. Clin Med Res. 2005;3:137–45.

    Article  CAS  Google Scholar 

  17. Anderson JL, Horne BD, Stevens SM, Grove AS, Barton S, Nicholas ZP, et al. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation. 2007;116:2563–70.

    Article  CAS  Google Scholar 

  18. Caraco Y, Blotnick S, Muszkat M. CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. Clin Pharm Ther. 2008;83:460–70.

    Article  CAS  Google Scholar 

  19. Huang SW, Chen HS, Wang XQ, Huang L, Xu DL, Hu XJ, et al. Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in Chinese patients. Pharmacogenet Genom. 2009;19:226–34.

    Article  CAS  Google Scholar 

  20. Burmester JK, Berg RL, Yale SH, Rottscheit CM, Glurich IE, Schmelzer JR, et al. A randomized controlled trial of genotype‐based Coumadin initiation. Genet Med. 2011;13:509–518.

    Article  CAS  Google Scholar 

  21. Borgman MP, Pendleton RC, McMillin GA, Reynolds KK, Vazquez S, Freeman A, et al. Prospective pilot trial of PerMIT versus standard anticoagulation service management of patients initiating oral anticoagulation. Thromb Haemost. 2012;108:561–9.

    Article  CAS  Google Scholar 

  22. Wang M, Lang X, Cui S, Fei K, Zou L, Cao J, et al. Clinical application of pharmacogenetic-based warfarin-dosing algorithm in patients of Han nationality after rheumatic valve replacement: a randomized and controlled trial. Int J Med Sci. 2012;9:472–9.

    Article  CAS  Google Scholar 

  23. Jonas DE, Evans JP, McLeod HL, Brode S, Lange LA, Young ML, et al. Impact of genotype-guided dosing on anticoagulation visits for adults starting warfarin: a randomized controlled trial. Pharmacogenomics. 2013;14:1593–603. https://doi.org/10.2217/pgs.13.145.

    Article  CAS  PubMed  Google Scholar 

  24. Kimmel SE, French B, Kasner SE, Johnson JA, Anderson JL, Gage BF, et al. A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med. 2013;369:2283–93.

    Article  CAS  Google Scholar 

  25. Li J, Liu S, Yang JH, GuoW, Wang ZZ, Chen Y, et al. A randomized controlled study of the VKORC1 and CYP2C9 genotypes in guiding warfarin therapy for pulmonary thromboembolism. Zhonghua Jie He He Hu Xi Za Zhi. 2013;36:950–3.

    PubMed  Google Scholar 

  26. Pirmohamed M, Burnside G, Eriksson N, Jorgensen AL, Toh CH, Nicholson T, et al. A randomized trial of genotype-guided dosing of warfarin. N Engl J Med. 2013;369:2294–303.

    Article  CAS  Google Scholar 

  27. Verhoef TI, Ragia G, de Boer A, Barallon R, Kolovou G, Kolovou V, et al. A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon. N Engl J Med. 2013;369:2304–12.

    Article  CAS  Google Scholar 

  28. Pengo V, Zambon CF, Fogar P, Padoan A, Nante G, Pelloso M, et al. A randomized trial of pharmacogenetic warfarin dosing in naive patients with non-valvular atrial fibrillation. PLoS ONE. 2015;10:e0145318.

    Article  Google Scholar 

  29. Supe S, Poljakovic Z, Bozina T, Ljevak J, Macolic Sarinic V, Bozina N. Clinical application of genotype-guided dosing of warfarin in patients with acute stroke. Arch Med Res. 2015;46:265–73.

    Article  Google Scholar 

  30. Jin H, Jiang F, Wei J, Yao Y, Yuan H, Yu M, et al. CYP2C9 and VKORC1 genotype-guided individualized warfarin therapy in Chinese patients with acute pulmonary thromboembolism: a randomized controlled clinical study. Int J Clin Exp Med. 2017;10:5595–602.

    CAS  Google Scholar 

  31. Wen MS, Chang KC, Lee TH, Chen YF, Hung KC, Chang YJ, et al. Pharmacogenetic dosing of warfarin in the Han-Chinese population: a randomized trial. Pharmacogenomics. 2017;18:245–53.

    Article  CAS  Google Scholar 

  32. Syn NL, Wong AL, Lee S, Teoh HL, Yip JWL, Seet RC, et al. Genotype-guided versus traditional clinical dosing of warfarin in patients of Asian ancestry: a randomized controlled trial. BMC Med. 2018;16:104 https://doi.org/10.1186/s12916-018-1093-8.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Makar-Aušperger K, Krželj K, Lovrić Benčić M, Radačić Aumiler M, Erdeljić Turk V, Božina N. Warfarin dosing according to the genotype-guided algorithm is most beneficial in patients with atrial fibrillation. Ther Drug Monit. 2018;40:362–8. https://doi.org/10.1097/ftd.0000000000000501.

    Article  PubMed  Google Scholar 

  34. Tse G, Gong M, Li G, Wong SH, Wu WKK, Wong WT, et al. Genotype-guided warfarin dosing vs. conventional dosing strategies: a systematic review and meta-analysis of randomized controlled trials. Br J Clin Pharm. 2018;84:1868–82.

    Article  CAS  Google Scholar 

  35. Yang T, Zhou Y, Chen C, Lu M, Ma L, Cui Y. Genotype‐guided dosing versus conventional dosing of warfarin: a meta‐analysis of 15 randomized controlled trials. J Clin Pharm Ther. 2019;44:197–208. https://doi.org/10.1111/jcpt.12782.

    Article  CAS  PubMed  Google Scholar 

  36. Kheiri B, Abdalla A, Haykal T, Osman M, Ahmed S, Hassan M, et al. Meta-analysis of genotype-guided versus standard dosing of vitamin K antagonists. Am J Cardiol. 2018;121:879–87.

    Article  Google Scholar 

  37. Vandell AG, Walker J, Brown KS, Zhang G, Lin M, Grosso M, et al. Genetics and clinical response to warfarin and edoxaban in patients with venous thromboembolism. Heart. 2017;103:1800–5.

    Article  CAS  Google Scholar 

  38. Antithrombotic therapy in patients with stable atherothrombosis. Recommendation of Russian Cardiology Society and National Society of Atherothrombosis. Cardiovascular Therapy and Prevention. 2009;8 Suppl 6:3–20.

  39. Flora DR, Rettie AE, Brundage RC, Tracy TS. CYP2C9 genotype-dependent warfarin pharmacokinetics: impact of CYP2C9 genotype on R- and S-warfarin and their oxidative metabolites. J Clin Pharm. 2017;57:382–93.

    Article  CAS  Google Scholar 

  40. Choi Q, Kim JE, Hyun J, Han KS, Kim HK. Contributions of procoagulants and anticoagulants to the international normalized ratio and thrombin generation assay in patients treated with warfarin: potential role of protein Z as a powerful determinant of coagulation assays. Thromb Res. 2013;132:e70–5.

    Article  CAS  Google Scholar 

  41. D’Angelo A, Della Valle P, Crippa L, Fattorini A, Pattarini E, ViganòD’Angelo S. Relationship between international normalized ratio values, vitamin K-dependent clotting factor levels and in vivo prothrombin activation during the early and steady phases of oral anticoagulant treatment. Haematologica. 2002;87:1074–80.

    PubMed  Google Scholar 

Download references

Acknowledgements

The authors appreciate the dedicated help of colleagues and nurses at the hospitals where this study was conducted and thank all participated patients. This study was partially supported by the Fund No. 8/3-280n-10 from the Moscow State Government and by funding from centers participated in this study.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Elizaveta Panchenko.

Ethics declarations

Conflict of interest

EP reports personal fees and nonfinancial support from Takeda, Pfizer, Boehringer Ingelheim, and Bayer during the conduct of the study; AD reports personal fees and nonfinancial support from Takeda, Instrumentation Laboratory, Diagnostica Stago during the conduct of the study; NV reports personal fees from Bayer, Pfizer, and Takeda, outside the submitted work during the conduct of the study; LG reports personal fees and nonfinancial support from Takeda, personal fees and nonfinancial support from Bayer, personal fees from Pfizer, during the conduct of the study; DZ reports personal fees and nonfinancial support from Takeda, AstraZeneca, Boehringer Ingelheim, and Bayer during the conduct of the study; IZ reports personal fees from Takeda, Pfizer, Boehringer Ingelheim, and Bayer during the conduct of the study; TV reports personal fees and nonfinancial support from Takeda, Pfizer, Boehringer Ingelheim, personal fees and Bayer during the conduct of the study; EK has nothing to disclose; ET has nothing to disclose; OZ has nothing to disclose; DT and IG are employees of DNA-Technology JSC, Moscow; GL has nothing to disclose; SS has nothing to disclose; NV has nothing to disclose; OS has nothing to disclose; AG has nothing to disclose.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Panchenko, E., Kropacheva, E., Dobrovolsky, A. et al. CYP2C9 and VKORC1 genotyping for the quality of long-standing warfarin treatment in Russian patients. Pharmacogenomics J 20, 687–694 (2020). https://doi.org/10.1038/s41397-020-0157-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41397-020-0157-2

This article is cited by

Search

Quick links